HIM
ADPT icon

Hillsdale Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

Hillsdale Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
684,217
+59,000
+9% +$904K 0.33% 57
2026
Q1 		$8.68M Buy
625,217
+8,267
+1% +$132K 0.24% 76
2025
Q4 		$10M Sell
616,950
-4,840
-0.8% -$79K 0.28% 57
2025
Q3 		$9.3M Buy
621,790
+53,700
+9% +$654K 0.28% 60
2025
Q2 		$6.62M Buy
+568,090
New +$5.16M 0.24% 82

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hillsdale Investment Management's ADPT Position: Q2 2026 in Review

Hillsdale Investment Management increased its Adaptive Biotechnologies (ADPT) stake by 9.4% in Q2 2026, buying an estimated $904K and bringing the position to 684,217 shares worth $14.7M. The position accounts for 0.33% of the portfolio, ranked #57.

Hillsdale Investment Management first reported a position in ADPT in Q2 2025 and has held it in 5 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Hillsdale Investment Management held 684,217 shares of Adaptive Biotechnologies worth $14.7M as of Q2 2026.
  • Hillsdale Investment Management bought 59,000 Adaptive Biotechnologies shares in Q2 2026, an estimated $904K.
  • Adaptive Biotechnologies made up 0.33% of Hillsdale Investment Management's portfolio in Q2 2026, its #57 holding.
  • Hillsdale Investment Management first reported a position in Adaptive Biotechnologies in Q2 2025 and has held it in 5 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.